Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly
Globe Newswire•26/10/2026•08:32 ET
0
Key Highlights
- ➤DARE-IDDS designed to store and deliver more than 100 discrete doses
- ➤Wireless connectivity may enable remote treatment monitoring and adjustment
- ➤DARE-IDDS initially targeted for contraception through DARE-LARC1
- ➤DARE-IDDS remains an investigational device in preclinical development
- ➤Daré collaborated with Cambridge Consultants to advance the platform
Expert Statements
Liz Proos, Vice President of Product Development at Daré Bioscience
“DARE-IDDS represents an opportunity to rethink how medications are delivered over the long term, particularly in therapeutic areas where adherence and treatment burden can limit the benefits of available therapies.”
Liz Proos, Vice President of Product Development at Daré Bioscience
“By bringing together programmable dosing, wireless connectivity and patient control in a single implantable device platform, we are working to advance a more flexible approach to drug delivery that has the potential to benefit patients, healthcare providers and future development and commercial partners.”
A single device designed to replace months to years of repeat injections, with potential applications well beyond its lead contraception program
VP of Product Development Liz Proos presents Friday, October 30, at 2:30 p.m. ET in Boston
Get started
Create a free account to read the full story.